Search

Introduction Preeclampsia (PE) is a disease with severe complications for the mother and neonate and amid all aspects related to the development of the disease, we highlight the angiogenic biomarkers. These markers are increasingly being studied to help in understanding the pathophysiology of PE, and of these markers is the PDGF AA, a protein directly involved in cell proliferation and migration of placental vasculogenesis. Objective This study aimed to determine the effectiveness of PDGF AA as a factor in PE prediction compared to serum biomarker levels in pregnant women who developed the disease and in healthy pregnant women. Methods This study is a case-control linked to a cohort, which included the participation of 1.417 pregnant women with gestational age between 20 and 25 weeks, who were interviewed and had blood collected for analysis before the development of the disease. Through interviews and medical record analysis (after delivery), we selected 30 women who had a confirmed diagnosis of preeclampsia and 90 healthy pregnant women. The dosage of PDGF AA was made to these participants and enabled us to analyze and compare the plasma concentration of this biomarker in healthy pregnant women and in women who developed preeclampsia. For the analysis of quantitative variables was used analysis of variance (ANOVA) and where this assumption was not observed, logarithmic transformations in the response variable were used. Results We found no significant difference in the age of pregnant women, BMI, gestational age and heart rate. The values of the comparison between the two groups showed a significant difference in systolic blood pressure ( p = 0.001) and diastolic ( p < 0.001) and mean pressure ( p < 0.001), where we found that the lowest values of these variables are of pregnant women not desenvoleram disease. The concentration of PDGF AA in pregnant women who developed PE subsequently was 257.7 ± 167.7 and in healthy patients was 337.80 ± 305.1 ( p = 0.48), no significant difference. Conclusion We conclude that serum levels of PDGF AA is not effective as a predictor of preeclampsia, since the difference observed between healthy pregnant women and pregnant women who developed the disease is not significant. [ABSTRACT FROM AUTHOR]

Objectives Pre-eclampsia, that affects 2–3% of pregnancies worldwide and develops after the twenty week of pregnancy, is characterized by increased blood pressure and proteinuria. When the worsening of the clinical frame occurs, the admission of these women, which can lead to a change in quality of life is recommended. To evaluate the quality of life of women with preeclampsia and healthy pregnant women hospitalized and compare them with each other, for the WHOQOL-Brev. Methods This was a case-control study. 58 patients were recruited, 28 with preeclampsia (blood pressure > 140 × 90 mmHg and 24-h proteinuria 300 mg) and 30 healthy. All responded to the quality of life WHOQOL-Brev questionnaire divided into four physical, psychological, social and environmental aspects. Results When comparing the clinical data of pregnant women, using the Mann–Whitney statistical difference was observed in the variables age p < 0.01 and gestational age p < 0.01. However when the variables come together no difference was observed. The same was observed when comparing the pregnant women in different aspects contained in the quality of life questionnaire. Conclusions The study showed that there was no statistical difference between groups in quality of life. The mean values between the two groups are equivalent; this can be explained because the PE pregnant women were hospitalized and receive multidisciplinary care. Disclosures M.S. Machado: None. T.V. Bertagnolli: None. J.S. Machado: None. C.H. Ferreira: None. G. Duarte: None. R.C. Cavalli: None. [ABSTRACT FROM AUTHOR]

Introduction Preeclampsia is a hypertensive disorder of pregnancy specific, its pathophysiology is not fully understood, however placental ischemia is considered a key factor for the development of the disease. This inadequate vascularization may be related to changes in the concentration of angiogenic factors in the maternal circulation. Among them angiopoietin 1 (Ang-1) and angiopoietin-2 (Ang-2) and act during angiogenesis. Objective To investigate the predictive ability of Ang-1 and Ang-2 in pregnant women with preeclampsia. Patients and methods This is a case-control study linked to a prospective cohort of pregnant women, with mean gestational age of 23 weeks, consisting of 90 healthy pregnant women (GS) and 30 pregnant women with preeclampsia (PE). Plasma concentrations of Ang-1 and Ang-2 were determined using the ELISA method. Results In the comparison of Ang-1 concentrations between GS and PE there was no statistical difference between the groups ( P = 0.604) the same was observed for Ang-2 ( P = 0919). Regarding the reason Ang-1/Ang-2, also no statistical difference ( P = 0.282). The predictive ability of the biomarkers was evaluated by ROC curve and the area under the curve for Ang-1, Ang-2 and Ang-1 ratio/Ang-2 were 0.47, 0.50 and 0.56 respectively. Conclusion Our study found no significant difference in the concentrations of Ang-1 and Ang-2 compared the PE group with the control group. And the ROC curves show that these biomarkers were not effective as preeclampsia predictors in our sample [ABSTRACT FROM AUTHOR]

Introduction Dysfunction of l -arginine/NO endothelial system is one of the factors that contribute to preeclampsia development. The supplementation with l -arginine could be used as treatment and/or prevention for this disorder. Objective To supplement pregnant women with preeclampsia and determine whether endogenous biomarkers can indicate which pregnant women will respond or not supplementation with l -arginine. Patients and methods We analyzed 56 pregnant women diagnosed with preeclampsia, divided into two groups 39 without supplementation and 17 who underwent supplementation with 3 g l -arginine orally for 10 days. Results The concentrations of the inflammation markers IL-6 and CRP were lower at the beginning of the supplementation when compared with the end of supplementation IL-6 (4.08 ± 3.74 vs. 10.67 ± 9.03, P = 0,03); PCR (5.52 ± 2.72 vs. 7.00 ± 3.37, P = 0.04). For other biomarkers analyzed we did not observe significant changes or the comparison between groups (sVCAM: P = 0.74; ADMA: P = 0.76; endoglin: P = 0 28; CD40: P = 0.22 and sFlt-1: P = .35) or between the beginning and the end of supplementation (sVCAM: P = 0.53; ADMA: P = 0.89; endoglin: P = 0.15; CD40: P = 0.53 and sFlt-1: P = 0.55). Conclusion The quantification of biomarkers showed that the participants were not responsive to supplementation with l -arginine since there was no change in the concentration thereof, or in the clinical and laboratory findings. [ABSTRACT FROM AUTHOR]

Objectives Pregnant women with preeclampsia, due to the complexity of the clinical frame remains at rest and such conduct leads to muscle discomfort, but no studies proving the safety and effectiveness of physical therapy protocols to improve such discomforts. To evaluate the influence of a physical therapy protocol applied in pregnant women with preeclampsia in relation to maternal and fetal hemodynamics Methods The women were randomized to the physiotherapy group or control group, both with conducting monitoring breast through pressure curve and measure heart rate and fetal monitoring with Doppler velocimetry. The physiotherapy group had the physiotherapy exercise protocol and received guidance on appropriate to stay in bed postures and the control group received only the guidelines. Results Data were analyzed using linear regression model with mixed effects (random and fixed effects). The data on the clinical data of the patients (age, gestational age, parity, BMI) and laboratory tests (24-h proteinuria, 24-h diuresis, creatinine, uric acid, urea, hemoglobin, bilirubin, sodium and potassium) showed no difference between groups. The results of maternal and fetal hemodynamics improved, however these changes are not clinically significant. Conclusions We can conclude that physiotherapy protocol we used is safe for both the mother and the fetus. Data monitoring of maternal and fetal hemodynamics Physiotherapy group Control group Materna hemodynamics: Pre mean Pos mean IC (95%) p Value Pre mean Pos mean IC (95%) p Value SBP (mmHg) Systolic blood pressure – mmHg 141,11 139,98 −3,405,53 0,64 137,36 141,97 -9,101,50 0,16 Diastolic blood pressure – mmHg 82,49 81,79 −2,794,54 0,64 80,95 83,22 −5,992,70 0,46 Average arterial pressure – mmHg 111,8 110,88 −2,634,56 0.6 109,15 112,59 −6,961,56 0.21 Heart rate – bpm 77,53 83,46 −8.40–1.93 <0.01 85,08 82,58 −4,903,93 0,83 Fetal hemodynamics: Pre mean Pos mean IC (95%) p Value Pre mean Pos mean IC (95%) p Value Middle cerebral artery – RI 0.79 0.75 0,010,08 0.02 0.76 0.7 0,010,09 0,03 Umbilical artery – RI 0,63 0,65 −0,090,03 0.33 0.65 0.68 −0,070,05 0.77 Disclosures T.V. Bertagnolli: None. M.S. Machado: None. J.S. Machado: None. C.H. Ferreira: None. G. Duarte: None. R.C. Cavalli: None. [ABSTRACT FROM AUTHOR]

Objectives Recent studies have shown that inadequate vascularization of the placenta may be caused by changes in the concentration of anti-angiogenic and pro-angiogenic factors like sFlt-1 and PlGF in maternal circulation indicating that they play an important role in the pathophysiology of preeclampsia. This study aimed evaluate the potential of sFlt-1 and PlGF as predictors of preeclampsia. Methods We studied 50 healthy pregnant women (HP) and 30 pregnant women with preeclampsia (PE) with a mean gestational age of 23 weeks. The measurements of concentrations of sFlt-1 and PlGF were determined using the ELISA method. Results When compared the concentrations of sFlt-1 to HP (135.08 pg/ml ± 76.4) and PE (186.55 pg/ml ± 182.4) no statistical difference between groups was observed p = 0.40. The concentrations of PlGF were greater in HP (483.17 pg/ml ± 381.7) compared to PE group (363.97 pg/ml ± 332.5), p = 0.01. Pulsatility index uterine artery average (right and left) was higher in the PE then in GS (1.05 ± 0.4 vs. 0.86 ± 0.4) p = 0.02 as expected pressure levels in the PE group were higher and the birth weight was lower in the PE group compared with the GS group. Conclusions Our study showed that despite not having a significant difference, the concentrations of sFlt-1 levels were higher in women from the PE group, the concentrations of PlGF were already lower in the PE group compared the HP, confirming that the variation in concentrations of factors anti-angionic and pro-angiogenic factors are involved in the pathophysiology of preeclampsia. Despite these results ROC curves show that these biomarkers were not effective as predictors of preeclampsia. Disclosures J.S. Machado: None. M.S. Machado: None. T.V. Bertagnolli: None. G. Duarte: None. V.C. Sandrim: None. R.C. Cavalli: None. [ABSTRACT FROM AUTHOR]